Abstract
We experienced a case of multi-drug resistant recurrent breast cancer with multiple bone metastases achieving a significant improvement by TS-1 and trastuzumab. The prior treatments including taxane or vinorelbine and trastuzumab were changed in the regimen to TS-1 and trastuzumab because of the progressive disease. TS-1 was administered orally at 100 mg/day everyday for 2 weeks, followed by a 1-week rest interval as 1 cycle, and trastuzumab was injected at 2 mg/kg/week for 4 weeks, followed by a 1-week rest interval as 1 cycle. After 3 cycles of the treatment, the level of tumor markers and tumor sizes of bone metastases became reduced. In conclusion, the combination treatment of TS-1 and trastuzumab is thought to be effective for multi-drug resistant recurrent breast cancer.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bone Neoplasms / drug therapy
-
Bone Neoplasms / secondary*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / metabolism
-
Breast Neoplasms / pathology
-
Breast Neoplasms / surgery
-
Carcinoma, Ductal, Breast / drug therapy*
-
Carcinoma, Ductal, Breast / metabolism
-
Carcinoma, Ductal, Breast / secondary
-
Carcinoma, Ductal, Breast / surgery
-
Drug Administration Schedule
-
Drug Combinations
-
Female
-
Humans
-
Lymph Nodes / pathology*
-
Lymphatic Metastasis
-
Mastectomy, Segmental
-
Middle Aged
-
Oxonic Acid / administration & dosage
-
Receptor, ErbB-2 / biosynthesis
-
Tegafur / administration & dosage
-
Trastuzumab
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Drug Combinations
-
S 1 (combination)
-
Tegafur
-
Oxonic Acid
-
Receptor, ErbB-2
-
Trastuzumab